Evidence map›Paper›PMID 33180114›Full record

Observational studyJAMA ophthalmology2021

Retinal Imaging Findings in Carriers With PSEN1-Associated Early-Onset Familial Alzheimer Disease Before Onset of Cognitive Symptoms.

Grayson W Armstrong, Leo A Kim, Filippos Vingopoulos, Jea Young Park, Itika Garg, Megan Kasetty, Rebecca F Silverman, Rebecca Zeng, Vivian Paraskevi Douglas, Francisco Lopera and 7 more

Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in JAMA ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Iris mammillations in Cri-du-chat syndrome.American journal of ophthalmology case reports · 2025
    Article
  3. Article
  4. Alzheimer's disease pathophysiology in the Retina.Progress in retinal and eye research · 2024
    Review
  5. Retinotopic degeneration of the retina and optic tracts in autosomal dominant Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Grayson W ArmstrongRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston.
Leo A KimRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston.
Filippos VingopoulosRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston.
Jea Young ParkHarvard Retinal Imaging Laboratory, Boston, Massachusetts.
Itika GargRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston.
Megan KasettyHarvard Retinal Imaging Laboratory, Boston, Massachusetts.
Rebecca F SilvermanHarvard Retinal Imaging Laboratory, Boston, Massachusetts.
Rebecca ZengHarvard Retinal Imaging Laboratory, Boston, Massachusetts.
Vivian Paraskevi DouglasRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston.
Francisco LoperaGrupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia.
Ana BaenaGrupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia.
Margarita GiraldoGrupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia.
Dan NortonDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.
Alice Cronin-GolombDepartment of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.
Joseph F Arboleda-VelasquezSchepens Eye Research Institute of Massachusetts Eye and Ear, Boston.
Yakeel T QuirozGrupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia.
John B MillerRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston.
Harvard University · USMassachusetts Eye and Ear Infirmary · USUniversidad de Antioquia · COBoston University · US

Funding

Relationship between tau pathology and cognitive impairment in autosomal dominant Alzheimer's diseaseR01AG054671 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2017 to 2021
$3.8M
Charting vascular contributions to white matter disease in familial Alzheimer's disease and CADASILRF1NS110048 · NINDS · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH, SEPULVEDA-FALLA, DIEGO · 2018 to 2019
$3.6M
Memory network dysfunction as an early marker of preclinical Alzheimer's DiseaseDP5OD019833 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2014 to 2018
$2.3M
Exploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant MiceUH3NS100121 · NINDS · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH · 2018 to 2020
$739k
NIA NIH HHS R01 AG054671NIH HHS DP5 OD019833NINDS NIH HHS RF1 NS110048NINDS NIH HHS UH3 NS100121
6 · The paper itself

Abstract

Importance: Individuals with autosomal dominant mutations for Alzheimer disease are valuable in determining biomarkers present prior to the onset of cognitive decline, improving the ability to diagnose Alzheimer disease as early as possible. Optical coherence tomography (OCT) has surfaced as a potential noninvasive technique capable of analyzing central nervous system tissues for biomarkers of Alzheimer disease. Objective: To evaluate whether OCT can detect early retinal alterations in carriers of the presenilin 1 (PSEN1 [OMIM 104311]) E280A mutation who are cognitively unimpaired. Design, Setting, and Participants: A cross-sectional imaging study conducted from July 13, 2015, to September 16, 2020, included 10 carriers of the PSEN1 E280A mutation who were cognitively unimpaired and 10 healthy noncarrier family members, all leveraged from a homogenous Colombian kindred. Statistical analysis was conducted from September 9, 2017, to September 16, 2020. Main Outcomes and Measures: Mixed-effects multiple linear regression was performed to compare the thickness values of the whole retina and individual retinal layers on OCT scans between mutation carriers and noncarriers. Simple linear-effects and mixed-effects multiple linear regression models were used to assess whether age was an effect modifier for PSEN1 mutation of amyloid β levels and retinal thickness, respectively. Fundus photographs were used to compare the number of arterial and venous branch points, arterial and venous tortuosity, and fractal dimension. Results: This study included 10 carriers of the PSEN1 E280A mutation who were cognitively unimpaired (7 women [70%]; mean [SD] age, 36.3 [8.1] years) and 10 healthy noncarrier family members (7 women [70%]; mean [SD] age, 36.4 [8.2] years). Compared with noncarrier controls, PSEN1 mutation carriers who were cognitively unimpaired had a generalized decrease in thickness of the whole retina as well as individual layers detected on OCT scans, with the inner nuclear layer (outer superior quadrant, β = -3.06; P = .007; outer inferior quadrant, β = -2.60; P = .02), outer plexiform layer (outer superior quadrant, β = -3.44; P = .03), and outer nuclear layer (central quadrant, β = -8.61; P = .03; inner nasal quadrant, β = -8.39; P = .04; inner temporal quadrant, β = -9.39; P = .02) showing the greatest amount of statistically significant thinning. Age was a significant effect modifier for the association between PSEN1 mutation and amyloid β levels in cortical regions (β = 0.03; P = .001) but not for the association between PSEN1 mutation and retinal thickness. No statistical difference was detected in any of the vascular parameters studied. Conclusions and Relevance: These findings suggest that OCT can detect functional and morphologic changes in the retina of carriers of familial Alzheimer disease who are cognitively unimpaired several years before clinical onset, suggesting that OCT findings and retinal vascular parameters may be biomarkers prior to the onset of cognitive decline.

Indexed as

MutationTomography, Optical CoherenceAdultAge of OnsetAlzheimer DiseaseBostonCase-Control StudiesCognitionColombiaCross-Sectional StudiesEarly DiagnosisFemaleGenetic Predisposition to DiseaseHumansMalePhenotypePresenilin-1PSEN1 protein, human

Identifiers

PMID33180114
PMCPMC7662482
OpenAlexW3106111826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.